Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 10, 2024
Reply to Z.R. McCaw et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Journal: British journal of clinical pharmacology
Published: February 01, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 30, 2023
Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
Journal: Endocrine
Published: March 01, 2018
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Journal: Clinical colorectal cancer
Published: September 11, 2014
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 11, 2013
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 17, 2012
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 12, 2012
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026